{"id":"NCT01448044","sponsor":"Bristol-Myers Squibb","briefTitle":"Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","officialTitle":"A Phase 3 Evaluation of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 4","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2013-10","completion":"2014-01","firstPosted":"2011-10-07","resultsPosted":"2015-09-07","lastUpdate":"2015-10-12"},"enrollment":152,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"BMS-790052 (NS5A Replication Complex Inhibitor)","otherNames":[]},{"type":"DRUG","name":"Placebo matching BMS-790052","otherNames":[]},{"type":"DRUG","name":"Pegylated-interferon alfa 2a","otherNames":["Pegasys"]},{"type":"DRUG","name":"Ribavirin","otherNames":["Copegus"]}],"arms":[{"label":"BMS-790052 + PegIFNα-2a + Ribavirin","type":"EXPERIMENTAL"},{"label":"Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the sustained virologic response at post treatment Week 12 for each cohort (BMS-790052/Pegylated-interferon alfa 2a (pegIFNα-2a)/Ribavirin (RBV) versus placebo/PegIFNα-2a/RBV).","primaryOutcome":{"measure":"Percentage of Participants With 12 Week Sustained Virologic Response (SVR12)","timeFrame":"Week 12 (Follow-up period)","effectByArm":[{"arm":"Daclatasvir + PegIFNα2a + Ribavirin","deltaMin":81.7,"sd":null},{"arm":"Placebo + PegIFNα2a + Ribavirin","deltaMin":42.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":26,"countries":["United States","France","Greece","Italy","Puerto Rico","Spain","United Kingdom"]},"refs":{"pmids":["26313445"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":82},"commonTop":["Asthenia","Headache","Pruritus","Influenza like illness","Anaemia"]}}